• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Lunit, AstraZeneca Partner to Develop AI-Powered Pathology Tools for Faster Lung Cancer Diagnostics

by Fred Pennic 11/18/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Advancing precision in lung cancer diagnostics: Lunit’s collaboration with AstraZeneca aims to transform the speed and accuracy of detecting actionable mutations in NSCLC. (Courtesy of Lunit)

What You Should Know: 

– Lunit, a provider of AI solutions for cancer diagnostics and therapeutics, has announced a strategic collaboration with AstraZeneca, a global pharmaceutical company, to develop AI-powered digital pathology solutions. 

– The partnership aims to improve cancer treatment by leveraging AI to analyze tissue samples and predict the likelihood of specific genetic mutations.

Focusing on Lung Cancer Treatment with AI

The collaboration will initially focus on developing Lunit SCOPE Genotype Predictor, an AI-powered tool that analyzes images of stained tissue samples to predict the likelihood of non-small cell lung cancer (NSCLC) driver mutations, such as those in the Epidermal Growth Factor Receptor (EGFR) gene.

Identifying these mutations is critical for determining the most effective treatment strategies for NSCLC patients. However, traditional genomic testing can be time-consuming and resource-intensive. Lunit SCOPE Genotype Predictor offers a faster and more cost-effective approach by:

  • Analyzing H&E Slides: Predicts the likelihood of EGFR and other NSCLC driver mutations directly from standard H&E-stained tissue slides.
  • Prioritizing Molecular Testing: Helps prioritize patients for molecular testing based on the AI’s prediction, potentially speeding up the diagnosis and treatment process.
  • Informing Treatment Decisions: Provides valuable insights to guide treatment decisions and personalize cancer care.

Empowering Healthcare Practitioners

By providing healthcare practitioners with cutting-edge AI tools, Lunit and AstraZeneca are empowering them to:

  • Optimize diagnostic workflows: Streamline the process of identifying patients with specific genetic mutations.
  • Prioritize molecular testing: Ensure that patients receive timely and appropriate testing.
  • Personalize cancer treatment: Select the most effective therapies based on individual genetic profiles.

“We are excited to partner with AstraZeneca, a leader in oncology therapeutics, to develop and evaluate this groundbreaking technology,” said Brandon Suh, CEO of Lunit. “The integration of Lunit SCOPE Genotype Predictor as a screening test into pathology workflows promises to improve the opportunity for patients to benefit from appropriate targeted therapy, ultimately improving patient outcomes and streamlining the treatment planning process.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |